news
Daiichi Sankyo’s edoxaban launched in the UK
10 July 2015 | By Victoria White
Edoxaban, a new blood-thinning drug therapy to help prevent stroke in patients with non-valvular atrial fibrillation, has been launched in the UK...
List view / Grid view
Daiichi Sankyo
news
EC approves Lixiana for stroke prevention in nonvalvular atrial fibrillation and for the treatment and prevention of DVT and PE
25 June 2015 | By Victoria White
The European Commission (EC) has granted Marketing Authorisation for Daiichi Sankyo’s Lixiana, an oral, once-daily selective factor Xa-inhibitor...
news
Urgent action needed to lessen the future impact of atrial fibrillation
2 June 2015 | By Victoria White
The Future of Anticoagulation Report highlights that urgent action is critical to lessening the potential impact of atrial fibrillation...
news
Half of heart stent patients don’t follow oral antiplatelet therapy regime as prescribed
29 April 2015 | By Victoria White
A recent survey has found that 52% of 275 ACS patients who were currently taking an oral antiplatelet have missed taking or changed the way they take it...
news
Swissmedic approves Lixiana for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
15 April 2015 | By Daiichi Sankyo
Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation...
news
Merger between Daiichi Sankyo subsidiary Ranbaxy and Sun Pharma completed
25 March 2015 | By Victoria White
Daiichi Sankyo have announced that the Sun Pharma and Ranbaxy merger process has been completed...
news
Daiichi Sankyo signs agreement with AstraZeneca to co-commercialise MOVANTIK in the US
20 March 2015 | By Victoria White
Daiichi Sankyo has announced a co-commercialisation agreement with AstraZeneca for MOVANTIK™ (naloxegol) in the US with plans to launch in April 2015..
news
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk
9 January 2015 | By Daiichi Sankyo
U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism...
news
Daiichi Sankyo launches new formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan
8 December 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets...
news
Daiichi Sankyo and Daiichi Sankyo Espha submit supplemental New Drug Application in Japan for “Cravit® Tablets, Granules” and “Levofloxacin Tablets, Granules DSEP”
1 October 2014 | By Daiichi Sankyo
Daiichi Sankyo Company Limited announced that it and its domestic generic subsidiary, Daiichi Sankyo Espha Co., Ltd. have submitted a supplemental New Drug Application (sNDA) in Japan...
news
Subgroup Analysis of ENGAGE AF-TIMI 48 explores the relationship between edoxaban dose, concentration, anti-factor Xa activity and outcomes
3 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48 study, that explores the relationship between edoxaban dose, concentration and anti-factor Xa activity in patients with non-valvular atrial fibrillation...
news
Daiichi Sankyo further expands TaNeDS collaborative Drug Discovery Program in Europe
2 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced details of the application for its Take a New Challenge for Drug Discovery Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe...
news
Launch of CANAGLU® Tablets 100mg
2 September 2014 | By Daiichi Sankyo
A SGLT2 inhibitor for Type2 Diabetes Mellitus...
news
Daiichi Sankyo announces cooperative sales agreement for the recombinant adsorbed hepatitis B vaccine “Bimmugen®”
28 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute on August 22 for its recombinant adsorbed hepatitis B vaccine (yeast-derived), Bimmugen®...
news
Initiation of Phase 3 trial of CHS-0214 (Investigational Etanercept Biosimilar) in Japan (RApsody)
18 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar1, in rheumatoid arthritis (the RApsody trial) in Japan...
